<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01907360</url>
  </required_header>
  <id_info>
    <org_study_id>HLD200-102</org_study_id>
    <nct_id>NCT01907360</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of HLD200 in Children and Adolescents With ADHD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironshore Pharmaceuticals and Development, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironshore Pharmaceuticals and Development, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to assess the pharmacokinetic effects of a single dose of HLD200&#xD;
      (methylphenidate hydrochloride) in children and adolescents with ADHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study utilized a single-center, open-label, single-treatment, fasted design to examine&#xD;
      the rate and extent of absorption of evening-administered HLD200 in children (6-12 years) and&#xD;
      adolescents (13-17 years) with ADHD.&#xD;
&#xD;
      Following a screening period that included five days washout to allow for clearance of any&#xD;
      prior ADHD medications, subjects were domiciled in-clinic and administered HLD200&#xD;
      (B-formulation; 54 mg; oral capsule) at 9 pm under fasted conditions. Subjects were then&#xD;
      observed for safety and tolerability and a total of 18 blood samples collected during a 48&#xD;
      hour period (at t=0, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24, 36 and 48 hours&#xD;
      post-dosing). These samples were then assayed for methylphenidate plasma concentrations and&#xD;
      this data used for calculation of pharmacokinetic parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-label, single-treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK Parameters for Rate and Extent of Absorption of MPH: Lag Time</measure>
    <time_frame>48hrs</time_frame>
    <description>The absorption lag time for methylphenidate in plasma expressed in hours is the difference in time between the drug administration and the last time point where the drug concentration was below the limit of assay quantitation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for Rate and Extent of Absorption of MPH: Cmax</measure>
    <time_frame>48hrs</time_frame>
    <description>The maximum drug concentration of methylphenidate in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for Rate and Extent of Absorption of MPH: Tmax</measure>
    <time_frame>48hrs</time_frame>
    <description>The time to reach maximum concentration of methylphenidate in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for Rate and Extent of Absorption of MPH: AUC0-tz</measure>
    <time_frame>48hrs</time_frame>
    <description>Area under the methylphenidate plasma concentration-time curve to time point tz (AUC0-tz), where tz was the last time point over the time interval with a measurable drug concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameters for Rate and Extent of Absorption of MPH:</measure>
    <time_frame>48hrs</time_frame>
    <description>The area under the methylphenidate plasma concentration-time curve to infinite time</description>
  </primary_outcome>
  <other_outcome>
    <measure>PK Parameters for Rate and Extent of Absorption of MPH in Plasma: Plasma Concentration-time Curve</measure>
    <time_frame>48hrs</time_frame>
    <description>To determine the rate and extent of absorption of methylphenidate following a single treatment of HLD200 (B formulation; 54 mg) in children and adolescents with ADHD, plasma samples were collected at t=0, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24, 36 and 48 hours post-HLD200 treatment and methylphenidate concentrations were determined.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Attention-Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>HLD200 (methylphenidate hydrochloride) in Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLD200 (B formulation, 54 mg, oral capsules) administered as a single treatment in the evening to children aged 13-17 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLD200 (methylphenidate hydrochloride) in Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLD200 (B formulation, 54 mg, oral capsules) administered as a single treatment in the evening to children aged 6-12 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLD200 (methylphenidate hydrochloride)</intervention_name>
    <arm_group_label>HLD200 (methylphenidate hydrochloride) in Adolescents</arm_group_label>
    <arm_group_label>HLD200 (methylphenidate hydrochloride) in Children</arm_group_label>
    <other_name>JORNAY PM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adolescents (13-17 years) and children (6-12 years).&#xD;
&#xD;
          -  Previous diagnosis of ADHD and confirmation using the Mini International&#xD;
             Neuropsychiatric Interview for Children and Adolescents (MINI-KID).&#xD;
&#xD;
          -  ADHD symptoms controlled on a stable dose of ADHD medication. Subjects should be on&#xD;
             MPH or have previous history of symptom control during treatment with MPH.&#xD;
&#xD;
          -  Physical examination free of clinically significant findings, unless deemed NCS by the&#xD;
             Investigator and Medical Monitor;&#xD;
&#xD;
          -  Able to swallow treatment capsules;&#xD;
&#xD;
          -  Available for entire study period;&#xD;
&#xD;
          -  Provision of informed consent (from the parent[s] and/or legal representative[s]) and&#xD;
             assent (from the subject); and&#xD;
&#xD;
          -  Female subjects of childbearing potential (i.e., post-menarche) required to have a&#xD;
             negative result on urine pregnancy testing (and will be given specific instructions on&#xD;
             avoiding pregnancy during trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known history or presence of significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurologic, ophthalmologic disease, unless deemed NCS by the Investigator and the&#xD;
             Medical Monitor;&#xD;
&#xD;
          -  Presence of any significant physical or organ abnormality;&#xD;
&#xD;
          -  Any illness during the 4 weeks before this study, unless deemed NCS by the&#xD;
             Investigator and the Clinical and/or Medical Monitor;&#xD;
&#xD;
          -  Severe comorbid psychiatric diagnosis that may affect subject safety or confound&#xD;
             results (e.g., psychosis, bipolar disorder);&#xD;
&#xD;
          -  Known history of moderate to severe asthma;&#xD;
&#xD;
          -  Known history of severe allergic reaction (including drugs, food, insect bites,&#xD;
             environmental allergens);&#xD;
&#xD;
          -  Known history of seizures (except febrile seizures prior to age 5), anorexia nervosa,&#xD;
             bulimia or current diagnosis or family history of Tourette's disorder;&#xD;
&#xD;
          -  Subject who are severely underweight or overweight.&#xD;
&#xD;
          -  Clinical value outside of the acceptable ranges, unless deemed NCS significant per the&#xD;
             Investigator;&#xD;
&#xD;
          -  Positive history for hepatitis B, hepatitis C and Human Immunodeficiency Virus (HIV);&#xD;
&#xD;
          -  Positive screening for illicit drug use, and/or current health conditions or use of&#xD;
             medications that might confound the results of the study or increase risk to the&#xD;
             subject;&#xD;
&#xD;
          -  Use of prescription medications (except ADHD medications) within 7 days and over-the&#xD;
             counter medications (except birth control) within the 3 days preceding study&#xD;
             enrollment, unless deemed acceptable by the Investigator and Clinical and/or Medical&#xD;
             Monitor;&#xD;
&#xD;
          -  Blood draws of 50 ml to 249 ml within the 30 days, 250 ml to 449 ml within the 45 days&#xD;
             and â‰¥ 450 ml within the 60 days preceding study enrollment;&#xD;
&#xD;
          -  Participation in clinical trial with an investigational drug within the 30 days&#xD;
             preceding study enrollment;&#xD;
&#xD;
          -  Intolerance to venipuncture; and&#xD;
&#xD;
          -  Current suicidal ideation or history of suicidality determined as a significant&#xD;
             finding on the Columbia-Suicide Severity Rating Scale (C-SSRS) by the investigator&#xD;
             (Baseline C-SSRS for adolescents; Pediatric Baseline C-SSRS for children).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Childress, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Psychiatry &amp; Behavioral Medicine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Psychiatry &amp; Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2013</study_first_posted>
  <results_first_submitted>July 2, 2021</results_first_submitted>
  <results_first_submitted_qc>August 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2021</results_first_posted>
  <disposition_first_submitted>September 7, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 7, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 15, 2017</disposition_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 29 subjects were enrolled (18 adolescents and 11 children in sequential cohorts). Following consent/assent and screening procedures, subjects were required to wash-out of all ADHD medications for 5 days prior clinic admission for testing.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adolescents (13-17yrs)</title>
          <description>Drug: B-HLD200 54mg capsules (Methylphenidate Modified Release B Formulation) or Drug: C-HLD200 54mg capsules (Methylphenidate Modified Release C Formulation)&#xD;
B-HLD200 54mg capsules&#xD;
C-HLD200 54mg capsules</description>
        </group>
        <group group_id="P2">
          <title>Children (6-12 Yrs)</title>
          <description>Drug: B-HLD200 54mg capsules (Methylphenidate Modified Release B Formulation) or Drug: C-HLD200 54mg capsules (Methylphenidate Modified Release C Formulation)&#xD;
B-HLD200 54mg capsules&#xD;
C-HLD200 54mg capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HLD200 (Methylphenidate Hydrochloride) in Adolescents</title>
          <description>HLD200 (B formulation, 54 mg, oral capsules) administered as a single treatment in the evening to adolescents aged 13-17 years.</description>
        </group>
        <group group_id="B2">
          <title>HLD200 (Methylphenidate Hydrochloride) in Children</title>
          <description>HLD200 (B formulation, 54 mg, oral capsules) administered as a single treatment in the evening to children aged 6-12 years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.4" spread="1.24"/>
                    <measurement group_id="B2" value="10.5" spread="1.37"/>
                    <measurement group_id="B3" value="13.52" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.56" spread="6.487"/>
                    <measurement group_id="B2" value="143.18" spread="6.072"/>
                    <measurement group_id="B3" value="159.55" spread="14.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.71" spread="14.588"/>
                    <measurement group_id="B2" value="36.08" spread="7.950"/>
                    <measurement group_id="B3" value="54.74" spread="19.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for Rate and Extent of Absorption of MPH: Lag Time</title>
        <description>The absorption lag time for methylphenidate in plasma expressed in hours is the difference in time between the drug administration and the last time point where the drug concentration was below the limit of assay quantitation.</description>
        <time_frame>48hrs</time_frame>
        <population>All enrolled subjects included in analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>HLD200 in Adolescents (13-17 Years)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54 mg) capsules</description>
          </group>
          <group group_id="O2">
            <title>HLD200 in Children (6-12 Yrs)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54mg) capsules</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for Rate and Extent of Absorption of MPH: Lag Time</title>
          <description>The absorption lag time for methylphenidate in plasma expressed in hours is the difference in time between the drug administration and the last time point where the drug concentration was below the limit of assay quantitation.</description>
          <population>All enrolled subjects included in analysis population.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="1.3"/>
                    <measurement group_id="O2" value="3.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for Rate and Extent of Absorption of MPH: Cmax</title>
        <description>The maximum drug concentration of methylphenidate in plasma.</description>
        <time_frame>48hrs</time_frame>
        <population>All enrolled subjects included in analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>HLD200 in Adolescents (13-17 Years)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54 mg) capsules</description>
          </group>
          <group group_id="O2">
            <title>HLD200 in Children (6-12 Yrs)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54mg) capsules</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for Rate and Extent of Absorption of MPH: Cmax</title>
          <description>The maximum drug concentration of methylphenidate in plasma.</description>
          <population>All enrolled subjects included in analysis population.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.17" spread="1.7"/>
                    <measurement group_id="O2" value="11.64" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for Rate and Extent of Absorption of MPH: Tmax</title>
        <description>The time to reach maximum concentration of methylphenidate in plasma.</description>
        <time_frame>48hrs</time_frame>
        <population>All enrolled subjects included in analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>HLD200 in Adolescents (13-17 Years)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54 mg) capsules</description>
          </group>
          <group group_id="O2">
            <title>HLD200 in Children (6-12 Yrs)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54mg) capsules</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for Rate and Extent of Absorption of MPH: Tmax</title>
          <description>The time to reach maximum concentration of methylphenidate in plasma.</description>
          <population>All enrolled subjects included in analysis population.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="2.5"/>
                    <measurement group_id="O2" value="17.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for Rate and Extent of Absorption of MPH: AUC0-tz</title>
        <description>Area under the methylphenidate plasma concentration-time curve to time point tz (AUC0-tz), where tz was the last time point over the time interval with a measurable drug concentration</description>
        <time_frame>48hrs</time_frame>
        <population>All enrolled subjects included in analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>HLD200 in Adolescents (13-17 Years)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54 mg) capsules</description>
          </group>
          <group group_id="O2">
            <title>HLD200 in Children (6-12 Yrs)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54mg) capsules</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for Rate and Extent of Absorption of MPH: AUC0-tz</title>
          <description>Area under the methylphenidate plasma concentration-time curve to time point tz (AUC0-tz), where tz was the last time point over the time interval with a measurable drug concentration</description>
          <population>All enrolled subjects included in analysis population.</population>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.5" spread="31.7"/>
                    <measurement group_id="O2" value="205.6" spread="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameters for Rate and Extent of Absorption of MPH:</title>
        <description>The area under the methylphenidate plasma concentration-time curve to infinite time</description>
        <time_frame>48hrs</time_frame>
        <population>All enrolled subjects included in analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>HLD200 in Adolescents (13-17 Years)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54 mg) capsules</description>
          </group>
          <group group_id="O2">
            <title>HLD200 in Children (6-12 Yrs)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54mg) capsules</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for Rate and Extent of Absorption of MPH:</title>
          <description>The area under the methylphenidate plasma concentration-time curve to infinite time</description>
          <population>All enrolled subjects included in analysis population.</population>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.6" spread="33.8"/>
                    <measurement group_id="O2" value="210.1" spread="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>PK Parameters for Rate and Extent of Absorption of MPH in Plasma: Plasma Concentration-time Curve</title>
        <description>To determine the rate and extent of absorption of methylphenidate following a single treatment of HLD200 (B formulation; 54 mg) in children and adolescents with ADHD, plasma samples were collected at t=0, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24, 36 and 48 hours post-HLD200 treatment and methylphenidate concentrations were determined.</description>
        <time_frame>48hrs</time_frame>
        <population>All enrolled subjects included in analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>HLD200 in Adolescents (13-17 Years)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54 mg) capsules</description>
          </group>
          <group group_id="O2">
            <title>HLD200 in Children (6-12 Yrs)</title>
            <description>Drug: HLD200 (methylphenidate hydrochloride; 54mg) capsules</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters for Rate and Extent of Absorption of MPH in Plasma: Plasma Concentration-time Curve</title>
          <description>To determine the rate and extent of absorption of methylphenidate following a single treatment of HLD200 (B formulation; 54 mg) in children and adolescents with ADHD, plasma samples were collected at t=0, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24, 36 and 48 hours post-HLD200 treatment and methylphenidate concentrations were determined.</description>
          <population>All enrolled subjects included in analysis population.</population>
          <units>(ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t=0 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=4 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.05" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=6 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.06"/>
                    <measurement group_id="O2" value="0.13" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=8 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.11"/>
                    <measurement group_id="O2" value="0.39" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=9 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.36"/>
                    <measurement group_id="O2" value="1.03" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=10 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.89"/>
                    <measurement group_id="O2" value="2.15" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=11 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="1.32"/>
                    <measurement group_id="O2" value="4.42" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=12 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="1.89"/>
                    <measurement group_id="O2" value="6.84" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t= 13 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="2.06"/>
                    <measurement group_id="O2" value="8.10" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=14 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" spread="2.02"/>
                    <measurement group_id="O2" value="9.05" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=15 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="1.90"/>
                    <measurement group_id="O2" value="9.68" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=16 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.58" spread="1.57"/>
                    <measurement group_id="O2" value="10.64" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=18 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" spread="1.43"/>
                    <measurement group_id="O2" value="11.01" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=20 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" spread="1.56"/>
                    <measurement group_id="O2" value="10.53" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=22 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="1.57"/>
                    <measurement group_id="O2" value="9.22" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=24 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="1.70"/>
                    <measurement group_id="O2" value="7.51" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=36 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.76"/>
                    <measurement group_id="O2" value="2.47" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t=48 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.30"/>
                    <measurement group_id="O2" value="0.48" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 48 hours after the HLD200 dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adolescents (13-17yrs)</title>
          <description>Drug: B-HLD200 54mg capsules (Methylphenidate Modified Release B Formulation) or Drug: C-HLD200 54mg capsules (Methylphenidate Modified Release C Formulation)</description>
        </group>
        <group group_id="E2">
          <title>Children (6-12 Yrs)</title>
          <description>Drug: B-HLD200 54mg capsules (Methylphenidate Modified Release B Formulation) or Drug: C-HLD200 54mg capsules (Methylphenidate Modified Release C Formulation)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen Impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Musculoskeletal And Connective Tissue Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Ironshore Pharmaceuticals and Development, Inc.</organization>
      <phone>13457498174</phone>
      <email>bev@ironshorepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

